185 related articles for article (PubMed ID: 30425069)
61. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
62. Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity.
Kousios A; Duncan N; Charif R; Roufosse C
J Am Soc Nephrol; 2018 Dec; 29(12):2901. PubMed ID: 30377233
[No Abstract] [Full Text] [Related]
63. [Recurrent invasive pneumococcal disease in a patient with IgG-κ smoldering multiple myeloma].
Chiba M; Oshimi K; Matsukawa T; Okada K; Miyagishima T
Rinsho Ketsueki; 2018; 59(1):40-44. PubMed ID: 29415936
[TBL] [Abstract][Full Text] [Related]
64. Management of asymptomatic myeloma patients.
Mateos MV
Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
[TBL] [Abstract][Full Text] [Related]
65. Early treatment for high-risk smouldering myeloma: has the time come?
Ludwig H
Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
[No Abstract] [Full Text] [Related]
66. The road to treating smoldering multiple myeloma.
Korde N; Mailankody S; Landgren O
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S59-64. PubMed ID: 25486957
[TBL] [Abstract][Full Text] [Related]
67. Prevalence, incidence and survival of smoldering multiple myeloma in the United States.
Ravindran A; Bartley AC; Holton SJ; Gonsalves WI; Kapoor P; Siddiqui MA; Hashmi SK; Marshall AL; Ashrani AA; Dispenzieri A; Kyle RA; Rajkumar SV; Go RS
Blood Cancer J; 2016 Oct; 6(10):e486. PubMed ID: 27768092
[No Abstract] [Full Text] [Related]
68. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
69. Early intervention effective in smouldering multiple myeloma.
Gourd E
Lancet Oncol; 2019 Dec; 20(12):e666. PubMed ID: 31679982
[No Abstract] [Full Text] [Related]
70. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.
Wichert S; Juliusson G; Johansson Å; Sonesson E; Teige I; Wickenberg AT; Frendeus B; Korsgren M; Hansson M
PLoS One; 2017; 12(2):e0171205. PubMed ID: 28158311
[TBL] [Abstract][Full Text] [Related]
71. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
72. Physicians, paraproteins and progress: diagnosis and management of myeloma.
Pawlyn C; Jackson GH
Br J Hosp Med (Lond); 2019 Feb; 80(2):91-98. PubMed ID: 30746991
[TBL] [Abstract][Full Text] [Related]
73. How We Approach Smoldering Multiple Myeloma.
Raje N; Yee AJ
J Clin Oncol; 2020 Apr; 38(11):1119-1125. PubMed ID: 32004107
[No Abstract] [Full Text] [Related]
74. Shall we treat smoldering multiple myeloma in the near future?
Landgren O
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):194-204. PubMed ID: 29222256
[TBL] [Abstract][Full Text] [Related]
75. Smoldering multiple myeloma: to treat or not to treat.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S
Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943
[TBL] [Abstract][Full Text] [Related]
76. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Grannis CH; Dewan VN; Wang RC
Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
[TBL] [Abstract][Full Text] [Related]
77. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; López Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Olavarría E; Quintana N; García JL; Bladé J; Lahuerta JJ; San Miguel JF
N Engl J Med; 2013 Aug; 369(5):438-47. PubMed ID: 23902483
[TBL] [Abstract][Full Text] [Related]
78. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
Giralt S; Stadtmauer E; McCarthy P
Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
[No Abstract] [Full Text] [Related]
79. Multiple myeloma: new options, new challenges.
Lacy MQ
Mayo Clin Proc; 2006 Jul; 81(7):877-9. PubMed ID: 16835966
[No Abstract] [Full Text] [Related]
80. The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI; Milani P; Derudas D; Buadi FK
Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
